WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525273
CAS#: 63394-05-8
Description: Plafibride is an antilipidemic and antiplatelet agent.
Hodoodo Cat#: H525273
Name: Plafibride
CAS#: 63394-05-8
Chemical Formula: C16H22ClN3O4
Exact Mass: 355.13
Molecular Weight: 355.819
Elemental Analysis: C, 54.01; H, 6.23; Cl, 9.96; N, 11.81; O, 17.99
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Plafibride
IUPAC/Chemical Name: 2-(4-Chlorophenoxy)-2-methyl-N-(morpholin-4-ylmethylcarbamoyl)propanamide
InChi Key: FRBJMGAXAFJVFP-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H22ClN3O4/c1-16(2,24-13-6-4-12(17)5-7-13)14(21)18-15(22)19(3)20-8-10-23-11-9-20/h4-7H,8-11H2,1-3H3,(H,18,21,22)
SMILES Code: CC(C)(OC1=CC=C(Cl)C=C1)C(NC(N(N2CCOCC2)C)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 355.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Filip M, Păduraru I, Nechifor M, Dănilă GH, Popovici I, Filip FM, Poşircă F. [The action of a fibric acid derivative on lipid metabolism]. Rev Med Chir Soc Med Nat Iasi. 1989 Jul-Sep;93(3):573-6. Romanian. PubMed PMID: 2636755.
2: Dănilă G, Nechifor M, Filip M, Păduraru I, Ifrim C, Grădinariu D, Papa V, Manolescu A, Bădescu A. [A clofibric acid derivative with hypolipemic and platelet antiaggregant action]. Rev Med Chir Soc Med Nat Iasi. 1988 Jan-Mar;92(1):127-32. Romanian. PubMed PMID: 3393745.
3: Rodriguez F, López IM, Jover E. Plafibride treatment and serum lipids in hyperlipoproteinemias. J Med. 1987;18(3-4):153-63. PubMed PMID: 3323393.
4: Joven J. [Plafibride--is it an effective drug as a hypolipemic agent?]. Med Clin (Barc). 1985 Apr 20;84(15):632. Spanish. PubMed PMID: 3999857.
5: Soringer Escofet FJ, Esteva de Antonio I. [Plafibride and vascular insufficiency of the lower limbs]. Med Clin (Barc). 1985 Apr 20;84(15):632. Spanish. PubMed PMID: 3999856.
6: Lázaro Campillo T, Gesto Castromil R, de la Sierra L, Pujadas J, Villafana W, Moreno R. [Therapy of vascular insufficiency of the legs with plafibride]. Med Clin (Barc). 1984 Dec 1;83(18):752-5. Spanish. PubMed PMID: 6521538.
7: Palou Monzo J, López-Delmás FJ. [Therapy of ischemic ulcers of the lower extremities using plafibride]. Angiologia. 1984 Nov-Dec;36(6):273-8. Spanish. PubMed PMID: 6517385.
8: Soler J, Vinzia C, Gómez JM, Morató J. [Plafibride treatment of hyperlipidemias type II and IV]. Med Clin (Barc). 1984 May 19;82(19):840-2. Spanish. PubMed PMID: 6738212.
9: Calatayud JM. Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain. Methods Find Exp Clin Pharmacol. 1983 Dec;5(10):707-14. PubMed PMID: 6672489.
10: Badimón JJ, Padró T, Cánovas M, Vidal M, Villaverde CA. Hypolipemic profile of plafibride in a model of experimental atherosclerosis. Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):613-7. PubMed PMID: 6668971.
11: Vilageliu J, Freixes J, Bruseghini L. Activity of plafibride on erythrocyte deformability. Arzneimittelforschung. 1983;33(3):401-4. PubMed PMID: 6683514.
12: Lasierra J, Díez MM, Fernández A, Viladés E, Gil M, Velázquez E. [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2]. Sangre (Barc). 1983;28(6):687-95. Spanish. PubMed PMID: 6424250.
13: Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)]. Med Clin (Barc). 1982 May 1;78(9):380-5. Spanish. PubMed PMID: 7047926.
14: Demichelis Genesio MA, Bracons R, Vicens B, Zapatero J, Bruseghini L. Clinical trials of plafibride in geriatric patients. Arzneimittelforschung. 1981;31(10a):1852-5. PubMed PMID: 7198465.
15: Santaniello E, Conti F, Vilageliu J, Bruseghini L. Bioavailability of plafibride in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1850-2. PubMed PMID: 7198464.
16: Dalmau J, Vicens B, Zapatero J, Bruseghini L. Plafibride tolerance trial in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1845-9. PubMed PMID: 7198463.
17: Dalmau J, Vicens B, Zapatero J, Bruseghini L. Plafibride tolerance trial at increasing doses in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1840-4. PubMed PMID: 7198462.
18: Zapatero J, Basi N, Vilageliu J, Sanfeliu C, Bruseghini L. Toxicological studies of plafibride. Part 4: Interaction of plafibride with other drugs. Arzneimittelforschung. 1981;31(10a):1835-8. PubMed PMID: 7198461.
19: Sanfeliu C, Zapatero J, Bruseghini L. Toxicological studies of plafibride. Part 3: Study of teratogenic activity in rats and rabbits. Arzneimittelforschung. 1981;31(10a):1831-4. PubMed PMID: 7198460.
20: Zapatero J, Sanfeliu C, Bruseghini L. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs. Arzneimittelforschung. 1981;31(10a):1819-30. PubMed PMID: 7198459.
